Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib + Cisplatin in Metastatic TNBC
NCT03012477Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of adavosertib in triple-negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Jan 2017; status: completed.
02
Drugs
adavosertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03012477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012477.